MeiraGTx (MGTX) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MeiraGTx (MGTX) has outperformed Taysha Gene Therapies (TSHA) over the past year, gaining 27.1% versus a loss of 12.5%. Over five years, MGTX leads with a -26.5% price change compared with -75.2% for TSHA. Taysha Gene Therapies is the larger company by market cap ($1.44 billion vs $1.01 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGTX | TSHA |
|---|---|---|
| Share price | $10.50 | $4.43 |
| Market cap | $1.01B | $1.44B |
| 1-day change | -2.96% | 0.00% |
| YTD return | +32.08% | -19.45% |
| 1-year return | +27.12% | -12.45% |
| 5-year return | -26.47% | -75.22% |
| P/E ratio (TTM) | 12.07 | — |
| EPS (TTM) | $0.87 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.77M |
| Revenue growth (YoY) | — | +17.28% |
| Net income (latest FY) | — | $-109.00M |
| Operating margin | — | -1130.65% |
| Net margin | — | -1115.27% |
| 52-week high | $15.35 | $7.30 |
| 52-week low | $6.62 | $3.69 |
| Distance from 52-week high | -31.60% | -39.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +164.29% | +193.45% |
| Average volume | 792.38K | 3.28M |
| Shares outstanding | 96.04M | 325.83M |
| Employees | 393 | 99 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGTX has outperformed TSHA by 39.6 percentage points over the past year.
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees
MGTX vs TSHA FAQ
Which is bigger, MeiraGTx or Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) is larger, with a market capitalization of $1.44B compared with $1.01B for MeiraGTx (MGTX).
Which stock has performed better over the past year, MGTX or TSHA?
MGTX returned +27.12% over the past 12 months, compared with -12.45% for TSHA (price return, excluding dividends). Past performance does not predict future results.
Are MeiraGTx and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.